Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Plaque Psoriasis · Rheumatoid Arthritis · CANF

Can Fite Biopharma

Can-Fite BioPharma

Can Fite Biopharma patent portfolio — 23 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA HQ
9 Employees
Public company Type
CANF · NYSE Ticker
Company details
Status
Public
HQ
10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA
Employees
9
Programs
20
Drugs
4
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Can Fite Biopharma patents

23 pharmaceutical patents indexed for Can Fite Biopharma. 4 expire within 24 months.

Can Fite Biopharma has 23 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 4 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

23 patents

Patent portfolio

  1. US 12213990

    A3 adenosine receptor ligand for use for achieving a fat loss effect

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11291681

    Method for treating fibrotic liver tissue using Cl-IB-MECA

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10780106

    Method for treating NASH accompanied by fibrosis using Cl-IB-MECA

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10265337

    Use of A3 adenosine receptor agonist in osteoarthritis treatment

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9549943

    A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9387220

    Method for inducing hepatocyte proliferation and uses thereof

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9102698

    Process for the synthesis of IB-MECA

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8987228

    Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8846635

    Method for inducing hepatocyte proliferation and uses thereof

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8557790

    A3 adenoside receptor agonists for the reduction of intraocular pressure

    Expires Mon Oct 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8541182

    Biological marker for inflammation

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7825102

    Treatment of dry eye conditions

    Expires Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7589075

    Use of an adenosine A3 receptor agonist for inhibition of viral replication

    Expires Mon Sep 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7465715

    Method for treatment of multiple sclerosis

    Expires Mon Dec 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7189706

    C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them

    Expires Mon Mar 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7141553

    A3AR agonists for the treatment of inflammatory arthritis

    Expires Mon Nov 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7112574

    C2,8-disubstituted adenosine derivatives and their different uses

    Expires Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7084127

    C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses

    Expires Mon Jul 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7064112

    Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

    Expires Mon Jun 15 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 6911435

    Method of treating leukopenia with adenosine

    Expires Mon Jun 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  21. US 6790839

    Pharmaceutical administration of adenosine agonists

    Expires Mon Sep 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  22. US 6638914

    Pharmaceutical administration of adenosine agonists

    Expires Mon Oct 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  23. US 6537587

    Compositions containing muscle-derived active agents

    Expires Mon Mar 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Can Fite Biopharma have?

23 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Can Fite Biopharma patents expire?

4 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.